How we work
How Monj tracks new weight loss medication in the UK
New weight loss medicines are usually discussed online long before they can be safely and legally prescribed to UK patients. Monj takes a deliberately slower approach: we track developments continuously, verify them against primary UK sources, and only reflect a change once it matters in real clinical and regulatory terms. This page explains exactly how that process works.
What “new” actually means in the UK
In everyday conversation, “new” can mean almost anything. In UK healthcare it has a much narrower meaning. Monj only treats a weight loss medicine as new when at least one of the following is true:
The medicine receives formal approval from the Medicines and Healthcare products Regulatory Agency following UK regulatory assessment.
Following approval, it enters a formal UK prescribing pathway that real patients can actually access.
It becomes genuinely available through pharmacies registered with the General Pharmaceutical Council.
An existing medicine gains an approved new use relevant to weight management.
The sources we monitor
| Source | What it tells us |
|---|---|
| MHRA | UK marketing authorisations, safety communications and Drug Safety Update alerts, the single most important trigger for change on our sites. |
| eMC (emc) | The UK Summary of Product Characteristics and Patient Information Leaflet for each medicine, the authoritative record of licensed doses, indications and side effects. |
| GPhC register | Whether a pharmacy offering a medicine is genuinely registered and lawfully operating, which underpins our pharmacy verification process. |
| NICE | Appraisals and guidance that shape NHS access and clinical positioning of weight loss medicines. |
| NHS & DHSC | NHS medicine pages, rollout announcements and policy changes that affect who can be prescribed what, and where. |
| UK pharmacy market | The prices, eligibility criteria and stock positions of GPhC-registered providers, checked on a rolling basis and reflected in our comparison tables. |
From rumour to published: the pipeline
- WatchlistA medicine in late-stage trials or under regulatory review is monitored in the background. Nothing is published as available. Foundayo (orforglipron) sat here throughout its UK assessment.
- Regulatory confirmationWe wait for the primary source itself: an MHRA authorisation, an updated SmPC on eMC, or a formal indication change. Secondary reporting is never sufficient on its own.
- Real-world availability checkApproval is not availability. We confirm that GPhC-registered UK pharmacies are actually offering the medicine through a lawful prescribing pathway, and at what price.
- Publication with sourcesOnly then do our comparison tables, guides and, where a medicine is significant enough, a dedicated comparison site go live, citing the underlying UK sources.
- Rolling re-verificationPrices, availability and safety information are re-checked on an ongoing schedule, and sooner whenever the MHRA issues new advice.
This process in practice
This is not theoretical. It is the process behind the medicines Monj and its sister sites track today:
- Mounjaro (tirzepatide) — tracked on Monj.co.uk, with rolling price verification across UK pharmacies
- Wegovy injection (semaglutide) — tracked on our sister site iGovy.co.uk
- Wegovy oral tablet — tracked on our sister site Ogovy.co.uk
- Foundayo (orforglipron) — added to coverage on Frayo.co.uk only after MHRA approval, having been watched throughout its UK regulatory assessment
When the next weight loss medicine completes UK approval, it will follow the same pipeline: watched quietly, verified against primary sources, then published with evidence.
Why we work this way
Patient safety
Publishing a medicine as “available” before a lawful UK pathway exists pushes people toward grey-market and counterfeit sellers. Our verification process exists to do the opposite.
Accuracy over speed
Being first matters less than being right. A price or availability claim on Monj should be checkable against the primary source it came from.
Independence
No manufacturer or pharmacy can pay to be described as “new”, “available” or “recommended”. Our independence statement sets out the full position.
Accountability
If we get something wrong, we correct it openly under the corrections process in our editorial and review policy.
Common questions
Why does Monj not list a medicine that has been approved in the US?
A US FDA approval does not make a medicine legally prescribable in the UK. Monj only reflects UK status: MHRA approval, a UK prescribing framework and genuine availability through GPhC-registered pharmacies. Overseas approvals are tracked as background only.
How quickly does Monj reflect a new UK approval?
Regulatory confirmation is usually reflected quickly, but our tables only show a medicine as available once real GPhC-registered pharmacies are lawfully offering it. Approval and availability are checked separately, because they are not the same thing.
Does Monj sell or prescribe any of these medicines?
No. Monj does not sell, prescribe or dispense medicines. We publish pricing and availability information about GPhC-registered UK providers, and clinical decisions always sit with a prescriber.